^
BIOMARKER:

HER-2 negative

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 negative
Gastric Cancer
cisplatin + capecitabine
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
CAPOX
Sensitive: A2 - Guideline
HER-2 negative
Gastric Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
docetaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
ixabepilone
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
everolimus
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
TC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + anastrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + letrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
palbociclib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
exemestane
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
EC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
CMF
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
AC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
TAC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
GT
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
epirubicin
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
cyclophosphamide oral
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
lyso-thermosensitive liposomal doxorubicin
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
HER-2 negative
Esophageal Cancer
XP
Sensitive: A2 - Guideline
HER-2 negative
Esophageal Cancer
FP
Sensitive: A2 - Guideline
HER-2 negative
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
POL 6326
Sensitive: B - Late Trials
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: B - Late Trials
HER-2 negative
Gastric Cancer
ramucirumab
Sensitive: B - Late Trials
HER-2 negative
Gastric Cancer
nivolumab
Sensitive: B - Late Trials
HER-2 negative
Breast Cancer
abemaciclib
Sensitive: B - Late Trials
HER-2 negative
HER2 Negative Breast Cancer
trastuzumab
Resistant: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
E7389-LF
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
rivoceranib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastric Cancer
rivoceranib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
capecitabine + vinorelbine tartrate
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
lapatinib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
cabazitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastric Cancer
camrelizumab
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
rivoceranib + camrelizumab
Sensitive: C2 – Inclusion Criteria
HER-2 negative
Gastric Cancer
rivoceranib + camrelizumab
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
docetaxel + doxorubicin hydrochloride
Resistant: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
MLN8237
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
rivoceranib
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
trastuzumab + bevacizumab
Sensitive: C2 – Inclusion Criteria
HER-2 negative
HER2 Negative Breast Cancer
GC
Sensitive: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
NLG8189
Resistant: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab + ME-344
Sensitive: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
APG-1387
Sensitive: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
gimeracil/oteracil/tegafur
Sensitive: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
nedaplatin
Sensitive: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
capecitabine + D19466
Sensitive: C3 – Early Trials
HER-2 negative
NSCLC
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 negative
HER2 Negative Breast Cancer
CDK4 inhibitor + CDK6 inhibitor
Sensitive: C4 – Case Studies
HER-2 negative
Estrogen Receptor Positive Breast Cancer
ZEN-3694
Sensitive: D – Preclinical
HER-2 negative
HER2 Negative Breast Cancer
etoposide IV
Sensitive: D – Preclinical